China Human Vaccine Industry Report, 2015-2018
  • Mar.2015
  • Hard Copy
  • USD $2,650
  • Pages:138
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM063
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,850
      

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies’ (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China’s human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.

However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume. Moreover, private and foreign brands hold a dominant position in the markets of Haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, and influenza vaccine, together making up 91.9%, 83.6%, 86.5%, and 69.5% in terms of lot release volume in 2014.

人用疫苗 英文_副本.png?

Being bullish about China’s demand for human vaccines and exports, many vaccine producers scale up efforts in vaccine R&D or expand capacity, such as Walvax Biotechnology. By early 2015, GMP on-site certification had been carried out for the company’s Diphtheria-tetanus-acellular pertussis combined vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and DTaP/Hib had made their way into clinical trials; the company is applying registration for meningococcal polysaccharide vaccine (Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru, Thailand, and India.

China Human Vaccine Industry Report, 2015-2018 highlights the following:
20120114.gifOperating environment, overall situation, sales channel, etc. of China human vaccine industry;
20120114.gifSupply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
20120114.gifSupply & demand, competitive landscape, and market prices of 10 product segments (including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine) in China;
20120114.gifOperation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

1 Overview of Vaccine Industry
1.1 Definition and Classification 
1.2 Industry Chain

2 Overview of China Human Vaccine Industry & Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.3 Status Quo
2.4 Supply & Demand
2.5 Competitive Landscape
2.6 Developments
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competitive Landscape
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Competitive Landscape
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competitive Landscape
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competitive Landscape
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competitive Landscape
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine 
3.6.1 Supply & Demand
3.6.2 Competitive Landscape
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competitive Landscape
3.7.3 Market Price
3.8 Pneumococca Vaccine
3.8.1 Supply & Demand
3.8.2 Competitive Landscape
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply & Demand
3.9.2 Competitive Landscape
3.9.3 Market Development & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competitive Landscape

4 China’s Import and Export of Vaccines 
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Destinations
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Sources of Imported Vaccines

5 Major Chinese Vaccine Producers
5.1 China National Biotec Group Co., Ltd.
5.1.1 Beijing Tiantan Biological Products Co., Ltd.
5.1.2 Chengdu Institute of Biological Products Co., Ltd.
5.1.3 Shanghai Institute of Biological Products Co., Ltd. 
5.1.4 Wuhan Institute of Biological Products Co., Ltd. 
5.1.5 Lanzhou Institute of Biological Products Co., Ltd. 
5.1.6 Changchun Institute of Biological Products Co., Ltd. 
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Customers and Suppliers
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.2.8 Development Prospect and Forecast
5.3 Chongqing Zhifei Biological Products Co., Ltd. 
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Major Customers
5.3.6 R&D and Investment
5.3.7 Development Prospect and Forecast
5.4 Walvax Biotechnology Co., Ltd. 
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Customers and Suppliers
5.4.6 R&D and Investment
5.4.7 Development Prospect and Forecast
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Major Customers
5.6.6 Liaoning Chengda Biotechnology Co., Ltd
5.6.7 Development Prospect and Forecast
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 NCPC GeneTech Biotechnology Development Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.13 Dalian Aleph Biomedical Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Beijing Minhai Biotechnology Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.15 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
5.15.1 Profile
5.15.2 Operation
5.16 Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.
Classification of Vaccines
Vaccine Industry Chain
Global Human Vaccine Market Size, 2008-2014
Revenue of Global Top5 Human Vaccine Producers, 2008-2014
Main Mergers & Acquisitions in Vaccine Industry Worldwide, 2005-2014
Policies on Vaccine Industry in China
Revenue and Total Profit of Bio-pharmaceutical Industry in China, 2007-2014
Chinese Human Vaccine Market Size, 2007-2014
Main Human Vaccine Varieties and Producers in China
Gross Margin of Vaccine Business of Major Vaccine Companies in China, 2007-2014
Lot Release Volume of EPI Vaccines and Extra EPI Vaccines, 2007-2014
China’s EPI Human Vaccine Market Shares by Lot Release Volume, 2008-2014
China’s Extra EPI Human Vaccine Market Shares by Lot Release Volume, 2008-2014
Vaccine Business Revenue of Major Vaccine Companies in China, 2011-2014
Human Vaccines under Review of CFDA, 2014
Events Related to Vaccine Business of Foreign Companies in China, 2011-2014
Diagram of Vaccine Distribution Channel in China
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2014
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2014
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2014
Market Price of Hepatitis B Vaccine in Some Parts of China, 2014
Epidemic Meningitis Morbidity and Mortality in China, 2008-2013
Meningococcal Vaccine Lot Release Volume in China by Type, 2007-2014
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2007-2014 (Million Doses)
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2009-2014(Million Bottles) 
Suppliers and Lot Release Volume of A+C Meningococcal Vaccine, 2007-2014
Suppliers and Lot Release Volume of ACYW135 Meningococcal Vaccine in China, 2008-2014
Market Prices of Meningococcal Vaccine in Some Parts of China, 2014 
Hepatitis A Morbidity and Mortality in China, 2008-2013
Hepatitis A Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of Hepatitis A Vaccine in China, 2007-2014
Market Prices of Hepatitis A Vaccine in Some Parts of China, 2014 
China’s Demand for Hepatitis A Vaccine, 2014-2018E
Influenza Morbidity and Mortality in China, 2008-2013
H1N1 Influenza Morbidity and Mortality in China, 2009-2012
Influenza Vaccine Lot Release Volume in China by Type, 2007-2014
Suppliers and Lot Release Volume of Influenza Split Vaccine in China, 2007-2014
Suppliers and Lot Release Volume of Subunit Influenza Vaccine in China, 2007-2012
Market Prices of Influenza Vaccine in Some Parts of China, 2014
Hib Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of Hib Vaccine in China, 2007-2014
Market Prices of Hib Vaccine in Some Parts of China, 2014
Sales Volume of Hib Vaccine in China, 2014-2018E
Rabies Morbidity and Mortality in China, 2007-2013
Human Rabies Vaccine Lot Release Volume in China, 2007-2014
Human Rabies Vaccine Lot Release Volume in China by Type, 2007-2014
Suppliers and Lot Release Volume of Human (Vero Cell) Rabies Vaccine in China, 2007-2014
Suppliers and Lot Release Volume of Human (BHK Cell) Rabies Vaccine in China, 2007-2014
Market Prices of Human Rabies Vaccine in Some Provinces of China, 2014
China’s Demand for Human Rabies Vaccine in China, 2013-2018E
Varicella Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of Varicella Vaccine in China, 2007-2014
Market Price of Varicella Vaccine in Some Parts of China, 2014
Pneumococcal Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of 7-valent and 23-valent Pneumococcal Vaccines in China, 2007-2014
Market Prices of Pneumococcal Vaccine in Some Parts of China, 2014
DPT Vaccine Lot Release Volume in China, 2007-2014
Acellular PDT Vaccine Lot Release Volume in China, 2007-2014
Poliomyelitis Vaccine Lot Release Volume in China, 2007-2014
Poliomyelitis Vaccine Suppliers and Lot Release Volume in China, 2007-2014
Export Volume and Value of Human Vaccines in China, 2009-2014
Average Export Prices of Human Vaccines in China, 2009-2014
Destinations of Exported Human Vaccines from China, 2014
Import Volume and Value of Human Vaccines in China, 2009-2014
Average Import Prices of Human Vaccines in China, 2009-2014
Sources of Imported Human Vaccines in China, 2014
Subsidiaries and Their Revenue and Profit of Beijing Tiantan Biological Products, 2014
Revenue and Operating Income of Beijing Tiantan Biological Products, 2007-2014
Revenue Breakdown of Beijing Tiantan Biological Products by Sector, 2007-2014
Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2007-2014
Beijing Tiantan Biological Products’ Procurement from Top5 Suppliers and % of Total Procurement, 2007-2014
Beijing Tiantan Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2007-2014
Gross Margin of Beijing Tiantan Biological Products by Sector, 2007-2014
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2009-2014
Vaccine Revenue of Beijing Tiantan Biological Products, 2007-2014
Vaccine Lot Release Volume Breakdown of Beijing Tiantan Biological Products by Product, 2009-2014
Revenue and Operating Income of Beijing Tiantan Biological Products, 2014-2018E
Vaccine Varieties of Chengdu Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2009-2014
Vaccine Varieties of Shanghai Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2009-2014
Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2009-2014
Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2009-2014
Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2009-2014
Revenue and Operating Income of Hualan Biological Engineering, 2007-2014
Revenue Breakdown of Hualan Biological Engineering by Sector, 2007-2014
Gross Margin of Hualan Biological Engineering by Product, 2007-2014
Hualan Biological Engineering’s Revenue from Top5 Customers and % of Total Revenue, 2007-2014
Hualan Biological Engineering’s Procurement from Top5 Suppliers and % of Total Procurement, 2007-2014
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2007-2014
Lot Release Volume Breakdown of Hualan Biological Engineering by Product, 2011-2014
Vaccine Revenue and Gross Margin of Hualan Biological Engineering, 2008-2014
Revenue and Operating Income of Hualan Biological Engineering, 2014-2018E
Subsidiaries and Main Products of Chongqing Zhifei Biological Products
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2008-2014
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2014
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2014
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2009-2014
Gross Margin of Chongqing Zhifei Biological Products, 2009-2014
Gross Margins of Chongqing Zhifei Biological Products’ Home-grown Vaccines, 2008-2014
Gross Margins of Chongqing Zhifei Biological Products’ Agent Vaccines, 2008-2014
Chongqing Zhifei Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2008-2014
Progress of the Products under Research of Chongqing Zhifei Biological Products by the end of 2014
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2014-2018E
Industrial Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2014
Vaccines on the Market and Capacities of Walvax Biotechnology
Revenue Breakdown of Walvax Biotechnology by Product, 2009-2014
Lot Release Volume Breakdown of Walvax Biotechnology by Product, 2009-2014
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2014
Gross Margin of Walvax Biotechnology by Product, 2007-2014
Walvax Biotechnology’s Revenue from Top5 Customers and % of Total Revenue, 2008-2014
Walvax Biotechnology’s Procurement from Top5 Suppliers and % of Total Procurement, 2008-2014
Progress of Projects under Construction of Walvax Biotechnology by the end of 2014
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2014
Progress of the Products under Research of Walvax Biotechnology by the end of 2014
Revenue and Operating Income of Walvax Biotechnology, 2014-2018E
Revenue and Operating Income of Sinovac Biotech, 2008-2014
Revenue Breakdown of Sinovac Biotech by Product, 2008-2014
Vaccine Lot Release Volume Breakdown of Sinovac Biotech by Product, 2009-2014
R&D Costs and % of Total Revenue of Sinovac Biotech, 2008-2013
Revenue and Operating Income of Liaoning Chengda, 2008-2014
Revenue Breakdown of Liaoning Chengda by Sector, 2008-2013
Revenue Breakdown of Liaoning Chengda by Region, 2008-2014
Gross Margin of Liaoning Chengda by Sector, 2008-2014
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2008-2014
Name List and Revenue Contribution of Liaoning Chengda’s Top 5 Customers, 2013
Human Vaccine Lot Release Volume of Liaoning Chengda Biotechnology, 2009-2014
Revenue and Net Income of Liaoning Chengda Biotechnology, 2012-2014
Revenue Structure of Liaoning Chengda Biotechnology by Product, 2012-2014
Name List and Revenue Contribution of Liaoning Chengda Biotechnology’s Top5 Customers, 2013-2014
Name List and Procurement Share of Liaoning Chengda Biotechnology’s Top5 Suppliers, 2013-2014
Revenue and Operating Income of Liaoning Chengda, 2014-2018E
Revenue and Operating Income of Changchun BCHT Biotechnology, 2009-2014
Vaccine Lot Release Volume Breakdown of Changchun BCHT Biotechnology by Product, 2009-2014
Lot Release Volume Breakdown of Changchun Changsheng Life Sciences by Product, 2008-2014
Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical
Vaccine Lot Release Volume Breakdown of Zhejiang Tianyuan Bio-Pharmaceutical by Product, 2009-2014
Revenue and Operating Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
Assets and Liabilities of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
Hepatitis B Vaccine Lot Release Volume Breakdown of Shenzhen Kangtai Biological Products by Dosage Form, 2007-2014
Vaccine Lot Release Volume Breakdown of Dalian Hissen Bio-pharm by Product, 2009-2014
Vaccines under Research of Dalian Hissen Bio-pharm, 2014
Vaccine Lot Release Volume of NCPC GeneTech Biotechnology Development, 2009-2014
Lot Release Volume of Dalian Aleph Biomedical, 2009-2014
Revenue and Operating Income of Dalian Aleph Biomedical, 2013-2014
Assets and Liabilities of Dalian Aleph Biomedical, 2013-2014
Vaccines under Research of Beijing Minhai Biotechnology
Vaccine Lot Release Volume Breakdown of Beijing Minhai Biotechnology by Product, 2009-2014
Revenue and Operating Income of Beijing Minhai Biotechnology, 2013-2014
Assets and Liabilities of Beijing Minhai Biotechnology, 2013-2014
Vaccine Lot Release Volume Breakdown of Shenzhen Sanofi Pasteur Biological Products by Product, 2009-2014
Revenue and Operating Income of Shenzhen Sanofi Pasteur Biological Products, 2013-2014
Assets and Liabilities of Shenzhen Sanofi Pasteur Biological Products, 2013-2014

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号